Literature DB >> 11673644

Absorption and excretion of orally administered inositol hexaphosphate (IP(6) or phytate) in humans.

F Grases1, B M Simonet, I Vucenik, R M Prieto, A Costa-Bauzá, J G March, A M Shamsuddin.   

Abstract

A study of the pharmacokinetic profile (oral absorption and renal excretion) of inositol hexaphosphate or phytate (IP(6)) is presented. Seven healthy volunteers were following a IP(6) poor diet (IP(6)PD) in a first period, and on IP(6) normal diet (IP(6)ND) in a second one. When following the IP(6)PD they become deficient in IP(6), the basal levels found in plasma (0.07+/- 0.01 mg/L) being clearly lower than those found when IP(6)ND was consumed (0.26+/- 0.03 mg/L). During the restriction period the maximum concentration in plasma were obtained 4 h after the ingestion of a single dose of IP(6), observing almost the same renal excretion profiles for the three different commercial sources and doses. After the IP(6) restriction period, volunteers were on IP(6)ND, reaching normal plasma and urinary IP(6) values in 16 days. Thus, the normal plasma and urinary concentrations, can be obtained either by consumption of a IP(6)ND taking a long time or in a short period by IP(6) supplements.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673644     DOI: 10.1002/biof.5520150105

Source DB:  PubMed          Journal:  Biofactors        ISSN: 0951-6433            Impact factor:   6.113


  28 in total

1.  Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.

Authors:  Joan Perelló; Miquel D Ferrer; Maria Del Mar Pérez; Nadine Kaesler; Vincent M Brandenburg; Geert J Behets; Patrick C D'Haese; Rekha Garg; Bernat Isern; Alex Gold; Myles Wolf; Carolina Salcedo
Journal:  Br J Pharmacol       Date:  2020-08-23       Impact factor: 8.739

2.  Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women.

Authors:  Angel A López-González; Félix Grases; Nieves Monroy; Bartolome Marí; Ma Teófila Vicente-Herrero; Fernando Tur; Joan Perelló
Journal:  Eur J Nutr       Date:  2012-05-22       Impact factor: 5.614

3.  A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.

Authors:  Carolina Salcedo; Pieter H Joubert; Miguel D Ferrer; Ana Z Canals; Francisco Maduell; Vicens Torregrosa; Josep Maria Campistol; Raquel Ojeda; Joan Perelló
Journal:  Br J Clin Pharmacol       Date:  2019-02-19       Impact factor: 4.335

Review 4.  Clinically Relevant Herb-Micronutrient Interactions: When Botanicals, Minerals, and Vitamins Collide.

Authors:  Bill J Gurley; Alyssa Tonsing-Carter; Sheila L Thomas; E Kim Fifer
Journal:  Adv Nutr       Date:  2018-07-01       Impact factor: 8.701

5.  The effect of combined inositol hexakisphosphate and inositol supplement in streptozotocin-induced type 2 diabetic rats.

Authors:  Shadae R Foster; Felix O Omoruyi; Juan Bustamante; Ruby L A Lindo; Lowell L Dilworth
Journal:  Int J Exp Pathol       Date:  2016-12-06       Impact factor: 1.925

6.  An experimental study on residual lithiasis after shock wave lithotripsy.

Authors:  A Costa-Bauzá; J Perelló; B Isern; F Grases
Journal:  Urol Res       Date:  2005-01-05

Review 7.  Phytate: impact on environment and human nutrition. A challenge for molecular breeding.

Authors:  Lisbeth Bohn; Anne S Meyer; Søren K Rasmussen
Journal:  J Zhejiang Univ Sci B       Date:  2008-03       Impact factor: 3.066

8.  Fibrinogen - a possible extracellular target for inositol phosphates.

Authors:  Thomas Grint; Andrew M Riley; Stephen J Mills; Barry V L Potter; Stephen T Safrany
Journal:  Messenger (Los Angel)       Date:  2012-12-01

9.  Role of inositol polyphosphates in programmed cell death.

Authors:  Rakhee Agarwal; Hamid Mumtaz; Nawab Ali
Journal:  Mol Cell Biochem       Date:  2009-03-26       Impact factor: 3.396

10.  Do mammals make all their own inositol hexakisphosphate?

Authors:  Andrew J Letcher; Michael J Schell; Robin F Irvine
Journal:  Biochem J       Date:  2008-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.